The hematocrit test devices market size has grown strongly in recent years. It will grow from $4.91 billion in 2025 to $5.22 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing prevalence of anemia and blood disorders, growth in hospital and laboratory diagnostic testing, rising demand for blood donor screening, expansion of emergency and trauma care services, growing awareness of hematocrit monitoring in clinical practice.
The hematocrit test devices market size is expected to see strong growth in the next few years. It will grow to $6.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising demand for point-of-care diagnostics, increasing burden of chronic and lifestyle-related diseases, expansion of decentralized healthcare and home-based testing, growing investments in diagnostic infrastructure, increasing focus on early disease detection and preventive healthcare. Major trends in the forecast period include rising adoption of point-of-care hematocrit testing devices, growing demand for rapid and accurate blood parameter assessment, increasing use of portable and handheld hematocrit meters, expansion of hematocrit testing in emergency and critical care settings, rising focus on routine screening and chronic disease monitoring.
The increasing instances of blood disorders are anticipated to drive the expansion of the hematocrit test devices market in the coming years. Blood disorders encompass conditions affecting the various components of human blood, such as red blood cells, white blood cells, platelets, and plasma. These disorders are becoming more prevalent due to a combination of factors including genetic factors, environmental pollution, and changes in lifestyle. Hematocrit test devices play a vital role in measuring the volume percentage of red blood cells in whole blood, offering essential insights into the patient's hematological well-being. For example, a report published by the American Cancer Society in January 2024 projects approximately 62,770 new cases of leukemia in the United States for 2024, leading to an estimated 23,670 deaths. Among these cases, around 20,800 new instances of acute myeloid leukemia (AML) are expected, predominantly affecting adults, with approximately 11,220 deaths attributed to AML, primarily occurring in adult patients. Thus, the rising occurrences of blood disorders are stimulating the growth of the hematocrit test devices market.
Major companies in the hematocrit test device market are focusing on advanced technologies, including user-friendly platforms tailored for medium-volume laboratories. A user-friendly platform is a system designed with intuitive features that enable fast operation with minimal training. For example, in March 2024, Mindray, a China-based health technology company, launched the BC-700 Series - a compact, integrated hematology analyzer for small to medium-sized labs that combines CBC and ESR testing in a single device. It delivers results in just 1.5 minutes, improving workflow efficiency. The system uses SF Cube 3D analysis technology for precise cell differentiation and incorporates the PLT-H parameter for enhanced platelet counting. By combining CBC and ESR testing in one unit, it reduces equipment and consumable costs. Available in both open vial and autoloader versions, the BC-700 Series provides reliable, automated, space-efficient testing with strong correlation to conventional methods, ensuring safety, accuracy, and repeatability.
In June 2023, Mars Incorporated, a US-based packaged food products manufacturer, acquired Heska Corporation for $1.3 billion. With this acquisition, Heska now operates under Mars Petcare's Science & Diagnostics division, expanding its reach in diagnostics and technology. The integration facilitates accelerated research and development efforts while enhancing global access to pet healthcare solutions. Heska Corporation specializes in manufacturing hematocrit test devices.
Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton Dickinson and Company, Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory LP, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.
North America was the largest region in the hematocrit test devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematocrit test devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the hematocrit test devices market by increasing costs for imported electronic components, sensors, reagents, and precision manufacturing equipment. These impacts are most visible in asia-pacific and north america, where global sourcing of diagnostic components is common. Higher costs have affected pricing for meters, analyzers, and consumables used by hospitals and diagnostic labs. However, tariffs are also encouraging local manufacturing, regional sourcing of consumables, and investments in domestic diagnostic production capabilities, supporting long-term supply chain stability.
The hematocrit test devices market research report is one of a series of new reports that provides hematocrit test devices market statistics, including hematocrit test devices industry global market size, regional shares, competitors with a hematocrit test devices market share, detailed hematocrit test devices market segments, market trends and opportunities, and any further data you may need to thrive in the hematocrit test devices industry. This hematocrit test devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hematocrit test devices are medical instruments utilized to measure the percentage of red blood cells (RBCs) in a person's total blood volume. These devices serve various purposes, including monitoring chronic conditions, preoperative assessments, detecting blood doping, screening blood donors, managing emergencies, and conducting research and clinical trials.
The primary types of hematocrit test devices include hematocrit test meters, hematocrit test analyzers, and reagents and consumables. A hematocrit (HCT) test meter is a point-of-care device employed to measure the percentage of red blood cells in whole blood. It finds applications in conditions such as anemia, polycythemia vera, congenital heart diseases, among others, and is utilized by various end-users, including hospitals and ambulatory surgical centers, clinics, diagnostic and pathology labs, among others.
The hematocrit test devices market consists of sales of hematocrit centrifuges, test strips, capillary transfer tubes, and adapter kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hematocrit test devices market size is expected to see strong growth in the next few years. It will grow to $6.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising demand for point-of-care diagnostics, increasing burden of chronic and lifestyle-related diseases, expansion of decentralized healthcare and home-based testing, growing investments in diagnostic infrastructure, increasing focus on early disease detection and preventive healthcare. Major trends in the forecast period include rising adoption of point-of-care hematocrit testing devices, growing demand for rapid and accurate blood parameter assessment, increasing use of portable and handheld hematocrit meters, expansion of hematocrit testing in emergency and critical care settings, rising focus on routine screening and chronic disease monitoring.
The increasing instances of blood disorders are anticipated to drive the expansion of the hematocrit test devices market in the coming years. Blood disorders encompass conditions affecting the various components of human blood, such as red blood cells, white blood cells, platelets, and plasma. These disorders are becoming more prevalent due to a combination of factors including genetic factors, environmental pollution, and changes in lifestyle. Hematocrit test devices play a vital role in measuring the volume percentage of red blood cells in whole blood, offering essential insights into the patient's hematological well-being. For example, a report published by the American Cancer Society in January 2024 projects approximately 62,770 new cases of leukemia in the United States for 2024, leading to an estimated 23,670 deaths. Among these cases, around 20,800 new instances of acute myeloid leukemia (AML) are expected, predominantly affecting adults, with approximately 11,220 deaths attributed to AML, primarily occurring in adult patients. Thus, the rising occurrences of blood disorders are stimulating the growth of the hematocrit test devices market.
Major companies in the hematocrit test device market are focusing on advanced technologies, including user-friendly platforms tailored for medium-volume laboratories. A user-friendly platform is a system designed with intuitive features that enable fast operation with minimal training. For example, in March 2024, Mindray, a China-based health technology company, launched the BC-700 Series - a compact, integrated hematology analyzer for small to medium-sized labs that combines CBC and ESR testing in a single device. It delivers results in just 1.5 minutes, improving workflow efficiency. The system uses SF Cube 3D analysis technology for precise cell differentiation and incorporates the PLT-H parameter for enhanced platelet counting. By combining CBC and ESR testing in one unit, it reduces equipment and consumable costs. Available in both open vial and autoloader versions, the BC-700 Series provides reliable, automated, space-efficient testing with strong correlation to conventional methods, ensuring safety, accuracy, and repeatability.
In June 2023, Mars Incorporated, a US-based packaged food products manufacturer, acquired Heska Corporation for $1.3 billion. With this acquisition, Heska now operates under Mars Petcare's Science & Diagnostics division, expanding its reach in diagnostics and technology. The integration facilitates accelerated research and development efforts while enhancing global access to pet healthcare solutions. Heska Corporation specializes in manufacturing hematocrit test devices.
Major companies operating in the hematocrit test devices market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton Dickinson and Company, Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory LP, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, Mikroscan Technologies Inc.
North America was the largest region in the hematocrit test devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematocrit test devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematocrit test devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the hematocrit test devices market by increasing costs for imported electronic components, sensors, reagents, and precision manufacturing equipment. These impacts are most visible in asia-pacific and north america, where global sourcing of diagnostic components is common. Higher costs have affected pricing for meters, analyzers, and consumables used by hospitals and diagnostic labs. However, tariffs are also encouraging local manufacturing, regional sourcing of consumables, and investments in domestic diagnostic production capabilities, supporting long-term supply chain stability.
The hematocrit test devices market research report is one of a series of new reports that provides hematocrit test devices market statistics, including hematocrit test devices industry global market size, regional shares, competitors with a hematocrit test devices market share, detailed hematocrit test devices market segments, market trends and opportunities, and any further data you may need to thrive in the hematocrit test devices industry. This hematocrit test devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hematocrit test devices are medical instruments utilized to measure the percentage of red blood cells (RBCs) in a person's total blood volume. These devices serve various purposes, including monitoring chronic conditions, preoperative assessments, detecting blood doping, screening blood donors, managing emergencies, and conducting research and clinical trials.
The primary types of hematocrit test devices include hematocrit test meters, hematocrit test analyzers, and reagents and consumables. A hematocrit (HCT) test meter is a point-of-care device employed to measure the percentage of red blood cells in whole blood. It finds applications in conditions such as anemia, polycythemia vera, congenital heart diseases, among others, and is utilized by various end-users, including hospitals and ambulatory surgical centers, clinics, diagnostic and pathology labs, among others.
The hematocrit test devices market consists of sales of hematocrit centrifuges, test strips, capillary transfer tubes, and adapter kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hematocrit Test Devices Market Characteristics
3. Hematocrit Test Devices Market Supply Chain Analysis
4. Global Hematocrit Test Devices Market Trends and Strategies
5. Hematocrit Test Devices Market Analysis of End Use Industries
7. Global Hematocrit Test Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hematocrit Test Devices Total Addressable Market (TAM) Analysis for the Market
9. Hematocrit Test Devices Market Segmentation
10. Hematocrit Test Devices Market Regional and Country Analysis
11. Asia-Pacific Hematocrit Test Devices Market
12. China Hematocrit Test Devices Market
13. India Hematocrit Test Devices Market
14. Japan Hematocrit Test Devices Market
15. Australia Hematocrit Test Devices Market
16. Indonesia Hematocrit Test Devices Market
17. South Korea Hematocrit Test Devices Market
18. Taiwan Hematocrit Test Devices Market
19. South East Asia Hematocrit Test Devices Market
20. Western Europe Hematocrit Test Devices Market
21. UK Hematocrit Test Devices Market
22. Germany Hematocrit Test Devices Market
23. France Hematocrit Test Devices Market
24. Italy Hematocrit Test Devices Market
25. Spain Hematocrit Test Devices Market
26. Eastern Europe Hematocrit Test Devices Market
27. Russia Hematocrit Test Devices Market
28. North America Hematocrit Test Devices Market
29. USA Hematocrit Test Devices Market
30. Canada Hematocrit Test Devices Market
31. South America Hematocrit Test Devices Market
32. Brazil Hematocrit Test Devices Market
33. Middle East Hematocrit Test Devices Market
34. Africa Hematocrit Test Devices Market
36. Hematocrit Test Devices Market Competitive Landscape and Company Profiles
37. Hematocrit Test Devices Market Other Major and Innovative Companies
40. Hematocrit Test Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hematocrit Test Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hematocrit test devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hematocrit test devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hematocrit test devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Hematocrit Test Meter; Hematocrit Test Analyzer; Reagents And Consumables2) By Application: Anemia; Polycythemia Vera; Congenital Heart Diseases; Other Applications
3) By End-User: Hospitals And Ambulatory Surgical Centers; Clinics; Diagnostic And Pathology Labs; Other End-Users
Subsegments:
1) By Hematocrit Test Meter: Handheld Hematocrit Meters; Portable Hematocrit Meters; Desktop Hematocrit Meters; Point-Of-Care Hematocrit Meters; Digital Hematocrit Meters; Battery-Powered Hematocrit Meters2) By Hematocrit Test Analyzer: Automated Hematocrit Analyzers; Benchtop Hematocrit Analyzers; Semi-Automated Hematocrit Analyzers; Microhematocrit Analyzers; High-Throughput Hematocrit Analyzers; Compact Hematocrit Analyzers
3) By Reagents And Consumables: Hematocrit Test Strips; Hematocrit Pipettes And Capillaries; Blood Sample Collection Tubes For Hematocrit Testing; Quality Control Reagents For Hematocrit Testing; Calibration Standards For Hematocrit Devices; Disposable Test Kits And Consumables
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthcare GmbH; Becton Dickinson and Company; Terumo Corporation; Beckman Coulter Inc.; Mindray Medical International Limited; bioMérieux SA; Sysmex Corporation; Horiba Ltd.; Nihon Kohden Corporation; Erba Mannheim; EKF Diagnostics Holding Plc.; Nova Biomedical Corporation; Boule Diagnostics AB; Stanbio Laboratory LP; Drucker Diagnostics; A. Menarini Diagnostics Srl; Sensa Core; Mikroscan Technologies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hematocrit Test Devices market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthcare GmbH
- Becton Dickinson and Company
- Terumo Corporation
- Beckman Coulter Inc.
- Mindray Medical International Limited
- bioMérieux SA
- Sysmex Corporation
- Horiba Ltd.
- Nihon Kohden Corporation
- Erba Mannheim
- EKF Diagnostics Holding Plc.
- Nova Biomedical Corporation
- Boule Diagnostics AB
- Stanbio Laboratory LP
- Drucker Diagnostics
- A. Menarini Diagnostics Srl
- Sensa Core
- Mikroscan Technologies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.22 Billion |
| Forecasted Market Value ( USD | $ 6.47 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
